PARItec

Company snapshot

PARItec maintains 248 tracked programs across Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterranean Fever (FMF), Acute mesenteric ischemia, Immune system disorders, PR3-ANCA granulomatosis with polyangiitis (Wegener’s), Pyelonephritis, Kidney Transplant recipients, newly diagnosed or relapsing deep venous thrombosis related to Behçet’s sy

• 248 active pipeline program(s) linked via ClinicalTrials.gov.
• 248 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for PARItec. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for PARItec.

1. Jun 8, 2026 Clinical update

   APHP220916 — Phase 2

2. Jun 8, 2026 Clinical update

   APHP211046 — Phase 3

3. Jun 8, 2026 Clinical update

   A phase 2 trial assessing Ifenprodil as a ReM... for Multiple sclerosis — Phase 2

4. Jun 8, 2026 Clinical update

   Kineret / solution for Familial Mediterranean Fever (F… — Phase 3

5. Jun 8, 2026 Clinical update

   P170916J — Phase 3

View all clinical trial activity →

• What is PARItec?

  Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterranean Fever (FMF), Acute mesenteric ischemia. NovaPharmaNews li

• Is PARItec publicly traded?

  PARItec appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does PARItec develop or market?

  We link 362 drug profile(s) where PARItec is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pari-pharma-gmbh#company-drugs.

• What are the latest developments for PARItec?

  In the last 12 months our linked public records show 248 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does PARItec focus on?

  PARItec focuses on Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction based on our analysis of their pipeline programs and drug development activities.